Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors
Didier Meulendijks, Ulrik N Lassen, Lillian L Siu, Alwin D R Huitema, Vaios Karanikas, Morten Mau-Sørensen, Derek J Jonker, Aaron R Hansen, Mary E Simcox, Kathleen J Schostack, Dean Bottino, Hua Zhong, Markus Roessler, Suzana M Vega-Harring, Tiantom Jarutat, David Geho, Karen Wang, Mark DeMario, Glenwood D Goss, Jan H M Schellens
Dive into the research topics of 'Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors'. Together they form a unique fingerprint.